Satsuma Pharmaceuticals is focused on developing innovative therapeutics for the acute treatment of migraines, with its lead product candidate being STS101, a dihydroergotamine (DHE) nasal powder. This product leverages Satsuma's proprietary powder technology and a specialized nasal delivery device, designed to enhance the clinical advantages of DHE while addressing the limitations of existing DHE formulations. The STS101 formulation incorporates a mucoadhesive drug carrier and engineered drug particle technologies, which aim to improve absorption and stability compared to liquid formulations. The company has conducted extensive clinical trials, including the Phase 3 SUMMIT and ASCEND trials, to evaluate the safety and efficacy of STS101, demonstrating promising pharmacokinetic profiles and favorable tolerability.

The clinical data from these trials indicate that STS101 may provide rapid and sustained relief from migraine symptoms, with a pharmacokinetic profile that shows higher DHE exposure compared to existing liquid nasal sprays and injectable products. Specifically, STS101 has demonstrated a quicker onset of action, achieving target plasma concentrations within 15 to 20 minutes and maintaining effective levels for at least two hours post-administration. This unique profile, combined with lower pharmacokinetic variability and a favorable safety profile, positions STS101 as a potentially differentiated treatment option for individuals suffering from migraines, aiming to deliver effective relief with minimal adverse effects.

United States

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Nervous System Diseases

Satsuma Pharmaceuticals

Migraines

STS101, is a drug-device combination of a proprietary dry-powder &nbsp;formulation of dihydroergotamine mesylate, or DHE, which is designed to &nbsp;be quickly and easily self-administered with a proprietary pre-filled, &nbsp;single-use, nasal delivery device. DHE products have long been &nbsp;recommended as a first-line therapeutic option for the acute treatment &nbsp;of migraine and have significant advantages over other therapeutics for &nbsp;many patients. However, broad use has been limited by invasive and &nbsp;burdensome administration and/or sub-optimal clinical performance of &nbsp;available injectable and liquid nasal spray products. STS101 is &nbsp;specifically designed to deliver the clinical advantages of DHE while &nbsp;overcoming these shortcomings.
<a href="https://investors.satsumarx.com/press-releases?item=50">Source</a>

Satsuma Pharmaceuticals

Company Details